icotec ag Receives Approvals for Two KONG® VBR Spinal Systems Made with BlackArmor® and Ti-iT® in Europe and the US

June 18, 2020

icotec ag announces that the KONG®-TL and the KONG®-C vertebral body replacement systems with the unique Titanium coating (Ti-iT®) receive FDA 510(k) clearance in the United States and CE approval in Europe.

icotec ag CEO Roger Stadler said, “This is exciting news for icotec ag and our team as it allows us to expand our portfolio in multiple countries simultaneously, to include implants made from radiolucent, nonmetallic BlackArmor® material with a 360° osseoconductive Ti-iT® pure titanium coating.”

The surgical replacement of vertebral bodies is a common procedure after the removal of tumors from the spinal column or after a serious spinal fracture. A vertebral body replacement implant (VBR) is used to reconstruct and stabilize the spinal column. The surgical requirements for these stabilization procedures are met by the broad, innovative and technology platform developed by icotec ag.

  • The fully modular design of these VBR systems with endplates in various profiles, sizes, angles and alignments complements the expandability afforded by the KONG®-TL VBR E (thoracolumbar) for the thoracic and lumbar spine providing surgeons with a great deal of flexibility in the surgical planning process. With the KONG®-C VBR for the cervical spine, the curved implant body ensures optimal adaptation to the anatomy of the patient.
  • The 360° Ti-iT® pure titanium coating from icotec ag allows for the rapid engraftment of bone onto the implant thanks to the optimized osseoconductive structure.
  • The unique icotec BlackArmor® Carbon/PEEK implant material enables artefact-free imaging to be carried out and, most notably, the improved planning, application, and follow-up care of radiotherapy for patients with tumors.

With over 15 years of clinical success and more than 40,000 implants made from the unique BlackArmor® material, icotec ag is the leading provider of Carbon/PEEK implants. As the global market leader in the surgical treatment of vertebral tumors, icotec ag has set a target of establishing a complete product portfolio that provides patients with improved therapy options. “With the imminent market launch of the KONG®-TL/C vertebral body replacement systems in Europe and the US, we have made significant strides toward achieving this target,” commented Roger. He continues, “These systems perfectly complement the icotec ag pedicle screw systems already in surgical use.”

 

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.